Cellution Biologics Inc. to acquire Elutia Inc.

Cellution Biologics Inc. has agreed to acquire the assets of Elutia Inc. in a transaction valued at $7.7 million. The deal structure involves a combination of cash and earn-out components, reflecting the headline offer price for the healthcare business. Both parties are based in the United States, indicating a domestic consolidation within the sector. This asset sale allows Cellution Biologics to expand its operational footprint by integrating Elutia’s specific assets into its existing portfolio. The agreement was publicly announced on 16 July 2026, marking a significant step in the strategic development of both entities involved in this healthcare-focused merger.

The transaction was completed on 17 August 2026, following the announcement period. This swift completion suggests that regulatory and internal approvals were secured without significant delay. The deal represents a clear acquisition of assets rather than a full equity purchase, which may have facilitated a more streamlined integration process for Cellution Biologics. By acquiring Elutia’s assets, Cellution aims to strengthen its position in the competitive healthcare market. The successful closure of this deal underscores the ongoing activity and consolidation trends within the US healthcare sector during this period.